These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 20108509)

  • 1. Effect of angiotensin II type 1 receptor antagonist valsartan on cardiac remodeling and left ventricular function in patients with acute ST-elevation myocardial infarction.
    Ovricenco E; Sinescu C; Dinescu S
    J Med Life; 2008; 1(3):323-33. PubMed ID: 20108509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
    Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both.
    Miyazaki S; Kasai T; Miyauchi K; Miyazaki T; Akimoto Y; Takagi A; Aihara K; Kawamura M; Suwa S; Kojima S; Sumiyoshi M; Daida H
    Circ J; 2010 Jun; 74(6):1158-64. PubMed ID: 20378999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
    Stephenson K; Skali H; McMurray JJ; Velazquez EJ; Aylward PG; Kober L; Van de Werf F; White HD; Pieper KS; Califf RM; Solomon SD; Pfeffer MA
    Heart Rhythm; 2007 Mar; 4(3):308-13. PubMed ID: 17341394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
    Shah AM; Claggett B; Prasad N; Li G; Volquez M; Jering K; Cikes M; Kovacs A; Mullens W; Nicolau JC; Køber L; van der Meer P; Jhund PS; Ibram G; Lefkowitz M; Zhou Y; Solomon SD; Pfeffer MA
    Circulation; 2022 Oct; 146(14):1067-1081. PubMed ID: 36082663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation.
    Thai H; Guarraia D; Johnson N; Goldman S; Gaballa MA
    J Cardiovasc Pharmacol; 2007 Dec; 50(6):703-7. PubMed ID: 18091589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.
    Verma A; Meris A; Skali H; Ghali JK; Arnold JM; Bourgoun M; Velazquez EJ; McMurray JJ; Kober L; Pfeffer MA; Califf RM; Solomon SD
    JACC Cardiovasc Imaging; 2008 Sep; 1(5):582-91. PubMed ID: 19356485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
    Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
    Ter Arkh; 2006; 78(8):14-20. PubMed ID: 17078211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valsartan in the treatment of heart attack survivors.
    Jugdutt BI
    Vasc Health Risk Manag; 2006; 2(2):125-38. PubMed ID: 17319456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study.
    Thune JJ; Køber L; Pfeffer MA; Skali H; Anavekar NS; Bourgoun M; Ghali JK; Arnold JM; Velazquez EJ; Solomon SD
    J Am Soc Echocardiogr; 2006 Dec; 19(12):1462-5. PubMed ID: 17138030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study.
    Suzuki H; Geshi E; Nanjyo S; Nakano H; Yamazaki J; Sato N; Tanaka K; Takano T; Yagi H; Shibata T; Mochizuki S; Katagiri T
    Circ J; 2009 May; 73(5):918-24. PubMed ID: 19346662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
    Bissessor N; White H
    Vasc Health Risk Manag; 2007; 3(4):425-30. PubMed ID: 17969373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction.
    Docherty KF; Campbell RT; Brooksbank KJM; Dreisbach JG; Forsyth P; Godeseth RL; Hopkins T; Jackson AM; Lee MMY; McConnachie A; Roditi G; Squire IB; Stanley B; Welsh P; Jhund PS; Petrie MC; McMurray JJV
    Circulation; 2021 Jul; 144(3):199-209. PubMed ID: 33983794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of angiotensin II type 2 receptor and limitation of myocardial stunning by angiotensin II type 1 receptor blockers during reperfused myocardial infarction in the rat.
    Jugdutt BI; Menon V
    J Cardiovasc Pharmacol Ther; 2003 Sep; 8(3):217-26. PubMed ID: 14506547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
    Pfeffer MA
    Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction: a possible mechanism of prevention of cardiac events by angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk myocardial infarction.
    Tani S; Nagao K; Anazawa T; Kawamata H; Furuya S; Takahashi H; Iida K; Matsumoto M; Kumabe N; Onikura M; Hirayama A
    Intern Med; 2009; 48(11):877-82. PubMed ID: 19483355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
    Wong M; Staszewsky L; Latini R; Barlera S; Volpi A; Chiang YT; Benza RL; Gottlieb SO; Kleemann TD; Rosconi F; Vandervoort PM; Cohn JN;
    J Am Coll Cardiol; 2002 Sep; 40(5):970-5. PubMed ID: 12225725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.